VLP Therapeutics
VLP Therapeutics is a Maryland-based biotech company founded in 2013, dedicated to developing next-generation vaccine technology to treat diseases that currently lack effective treatments. Their mission is to address unmet medical needs worldwide and expand the frontiers of vaccine treatment, with a focus on cancer and infectious diseases such as influenza, malaria, and dengue.
Industries
Nr. of Employees
small (1-50)
VLP Therapeutics
704 Quince Orchard Rd., Suite 110, Gaithersburg, MD 20878, United States
Patents
Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
US-11345726-B2
View Details
Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
US-11345726-B2
View DetailsProducts
Dengue virus-like particle (VLP) vaccine candidate
A multivalent VLP-based dengue vaccine candidate shown to induce neutralizing antibodies and reduce viral replication in non-human primate studies.
Self-amplifying RNA vaccine candidates and booster formulations
Replicon/self-amplifying RNA vaccine candidates (applications include SARS-CoV-2 boosters and influenza) with work on nucleotide modification and lyophilized formulations for patch delivery.
Cancer vaccine and replicon-based immunotherapy candidates
VLP-based cancer vaccine concepts and replicon particles engineered to express immunomodulatory cytokines to reprogram tumor-associated immune cells and induce anti-tumor responses.
Dengue virus-like particle (VLP) vaccine candidate
A multivalent VLP-based dengue vaccine candidate shown to induce neutralizing antibodies and reduce viral replication in non-human primate studies.
Self-amplifying RNA vaccine candidates and booster formulations
Replicon/self-amplifying RNA vaccine candidates (applications include SARS-CoV-2 boosters and influenza) with work on nucleotide modification and lyophilized formulations for patch delivery.
Cancer vaccine and replicon-based immunotherapy candidates
VLP-based cancer vaccine concepts and replicon particles engineered to express immunomodulatory cytokines to reprogram tumor-associated immune cells and induce anti-tumor responses.
Services
Design and execution of preclinical studies including immunogenicity, safety, and efficacy testing in animal models (including non-human primates).
Clinical program management and execution including initiation of late-stage clinical trials for RNA vaccine candidates.
Research collaborations with academic institutions and research centers to advance vaccine discovery and development.
Design and execution of preclinical studies including immunogenicity, safety, and efficacy testing in animal models (including non-human primates).
Clinical program management and execution including initiation of late-stage clinical trials for RNA vaccine candidates.
Research collaborations with academic institutions and research centers to advance vaccine discovery and development.
Expertise Areas
- Vaccine development (infectious disease and cancer)
- Self-amplifying RNA / replicon platform development
- Virus-like particle (VLP) vaccine engineering
- Preclinical and clinical development and trial management
Key Technologies
- Virus-like particles (VLPs)
- Self-amplifying (replicon) RNA
- Lyophilization (vaccine stabilization)
- Microneedle array patch delivery
News & Updates
Research by VLP Therapeutics and colleagues at Stanford University posted as a preprint on August 11, 2025.
Research by VLP Therapeutics and colleagues at Stanford University and the University of North Carolina at Chapel Hill, reported online ahead of print.
VLP Therapeutics announced receiving an investment of about US$6 million from the GHIT Fund for a Phase 2 dengue vaccine clinical trial.
Research demonstrating that immunization of monkeys with a tetravalent dengue virus-like particle-based vaccine induces antibodies and reduces viral replication.
Research on safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, conducted by VLP Therapeutics Japan.
VLP Therapeutics Japan announced the start of a Phase 3 clinical trial for a COVID-19 booster targeting Omicron XBB.1.5.
Research by VLP Therapeutics and colleagues at Stanford University posted as a preprint on August 11, 2025.
Research by VLP Therapeutics and colleagues at Stanford University and the University of North Carolina at Chapel Hill, reported online ahead of print.
VLP Therapeutics announced receiving an investment of about US$6 million from the GHIT Fund for a Phase 2 dengue vaccine clinical trial.
Research demonstrating that immunization of monkeys with a tetravalent dengue virus-like particle-based vaccine induces antibodies and reduces viral replication.
Research on safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, conducted by VLP Therapeutics Japan.
VLP Therapeutics Japan announced the start of a Phase 3 clinical trial for a COVID-19 booster targeting Omicron XBB.1.5.